Patent Allowance by European Patent Office

Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Lukemia (ALL), announced that the European Patent Office (“EPO”) has indicated on September 15, 2016 that it intends to grant a patent relating to Curewize’s ProALL technology.  The patent will be based on patent application number 11779491.7, which is assigned to Mor Research Applications Ltd. and  licensed to Curewize Health Ltd. The application broadly covers methods of prognosis relating to ProALL technology based on novel methods using micro-RNA for determining prognosis and treatment regimen required by individual patients. This announcement of intent to grant is indicative of the broad protection that the ProALL product will benefit from in many jurisdictions worldwide.